Insight, China's Pharmaceutical Industry

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Jiangsu Chia Tai  Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of China‑listed Sino Biopharmaceutical Ltd....

Company Drug

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Fineline Cube Oct 13, 2025

Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...

Company Drug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Fineline Cube Oct 13, 2025

China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...

Company Drug

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Fineline Cube Oct 13, 2025

China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...

Company Deals

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Fineline Cube Oct 13, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune, Inc....

Drug

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 13, 2025

Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Drug

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor

Fineline Cube Oct 13, 2025

The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received...

Drug Medical Device Policy / Regulatory

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

Fineline Cube Oct 13, 2025

The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...

Company Deals Drug

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Fineline Cube Oct 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...

Company Medical Device

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

Fineline Cube Oct 11, 2025

Peijia Medical Limited (HKG: 9996) announced today that the National Medical Products Administration (NMPA) of...

Company Deals Drug

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Fineline Cube Oct 11, 2025

PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...

Company Deals

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million

Fineline Cube Oct 11, 2025

China‑based Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347) announced that it and its subsidiary Jiaxing...

Company Legal / IP

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

Fineline Cube Oct 11, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...

Company Drug Policy / Regulatory

National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai

Fineline Cube Oct 11, 2025

The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...

Company Deals

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin

Fineline Cube Oct 10, 2025

Novo Nordisk A/S (NYSE: NVO) announced today that it will acquire Akero Therapeutics (NASDAQ: AKRO) for...

Company Drug

Xingqi Pharma Secures NMPA Approval for SQ‑129, a Novel Treatment for Diabetic Macular Edema

Fineline Cube Oct 10, 2025

China‑based Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced today that the China National Medical...

Company Drug

Shanghai Henlius Biotech Achieves Primary Endpoint in Phase 3 Trial of Serplulimab for Early‑Stage Gastric Cancer

Fineline Cube Oct 10, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) today announced that its phase 3, randomized, double‑blind, multi‑center study...

Company Drug

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

Fineline Cube Oct 10, 2025

JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...

Company Medical Device

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Fineline Cube Oct 10, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced on October 7, 2025 that its Endovenous Radiofrequency Ablation System...

Company Drug

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Fineline Cube Oct 10, 2025

Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...

Insight, China's Pharmaceutical Industry

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin

Xingqi Pharma Secures NMPA Approval for SQ‑129, a Novel Treatment for Diabetic Macular Edema

Shanghai Henlius Biotech Achieves Primary Endpoint in Phase 3 Trial of Serplulimab for Early‑Stage Gastric Cancer

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

You Missed

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix